Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;54(1):19-24.
doi: 10.1177/0009922814542481. Epub 2014 Jul 14.

Topiramate for weight reduction in adolescents with severe obesity

Claudia K Fox  1 , Kara L Marlatt  2 , Kyle D Rudser  2 , Aaron S Kelly  2
Affiliations

Topiramate for weight reduction in adolescents with severe obesity

Claudia K Fox et al. Clin Pediatr (Phila). 2015 Jan.

Abstract

Background: Medications for use as an adjunct to lifestyle modification therapy (LSM) for severe adolescent obesity are limited. Topiramate results in weight reduction in adults with obesity, but has not been studied in adolescents.

Objective: To examine the effect of topiramate plus LSM on body mass index (BMI) reduction in adolescents with severe obesity.

Methods: Data for this retrospective chart review were collected from patients attending a pediatric weight management program who were treated with LSM plus topiramate for 3 months minimum. Mean BMI percent change from baseline was evaluated using t-tests.

Results: Twenty-eight patients (mean age 15.2 ± 2.5 years, mean baseline BMI 46.2 ± 10.3 kg/m(2)) were identified for inclusion. The 6-month percent change in BMI was -4.9, 95% confidence interval (-7.1, -2.8), P < .001.

Conclusions: Topiramate with concurrent LSM was associated with clinically meaningful BMI reduction in adolescents with severe obesity. Randomized controlled clinical trials examining efficacy and safety of topiramate for severe obesity in adolescents are needed.

Keywords: adolescent; medication; obesity; pharmacotherapy; topiramate.

PubMed Disclaimer

Figures

Figure
Figure
BMI Percent Change from Baseline to 3-Months and 6-Months for the Overall and Topiramate Only Groups. Bold lines present group means with 95% confidence intervals at 3 and 6 months; lighter lines present individual trajectories.
See this image and copyright information in PMC

Comment in

References

    1. Freedman DS, Mei Z, Srinivasan SR, Berenson GS, Dietz WH. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: The Bogalusa Heart Study. J Pediatr. 2007;150(1):12–17e2. - PubMed
    1. Flegal KM, Wei R, Ogden CL, Freedman DS, Johnson CL, Curtin LR. Characterizing extreme values of body mass index-for-age by using the 2000 Centers for Disease Control and Prevention growth charts. Am J Clin Nutr. 2009;90(5):1314–1320. - PubMed
    1. Koebnick C, Smith N, Coleman KJ, et al. Prevalence of extreme obesity in a multiethnic cohort of children and adolescents. J Pediatr. 2010;157(1):26–31e2. - PMC - PubMed
    1. Madsen KA, Weedn AE, Crawford PB. Disparities in peaks, plateaus, and declines in prevalence of high BMI among adolescents. Pediatrics. 2010;126(3):434–442. - PMC - PubMed
    1. Skinner AC, Skelton JA. Prevalence and trends in obesity and severe obesity among children in the United States, 1999–2012. JAMA Pediatr. 2014 doi: 10.1001/jamapediatrics.2014.21. - DOI - PubMed

Publication types